Metaplastic breast cancers: Genomic profiling, mutational burden and tumor-infiltrating lymphocytes

Nancy Tray, Jessica Taff, Baljit Singh, James Suh, Nhu Ngo, Maryann Kwa, Andrea B. Troxel, Young Kwang Chae, Razelle Kurzrock, Sandip Pravin Patel, Elad Sharon, Carsten Denkert, Jeffrey S. Ross, Sylvia Adams*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

16 Scopus citations


Metaplastic breast cancer (MPBC) is a rare subtype that accounts for <1% of all breast cancers. Although these are typically “triple negative,” they are relatively chemotherapy-refractory compared to conventional triple negative invasive breast cancers with more aggressive features and an overall poor prognosis. MPBC is a heterogeneous group of tumors that are enriched for TP53 and PIK3CA mutations, and have been found to have high PD-L1 expression though the mechanisms underlying its immunogenicity remain unclear. We perform comprehensive genomic profiling in the largest MPBC dataset (n = 192) to date and assess for other potential biomarkers of immune response.

Original languageEnglish (US)
Pages (from-to)29-32
Number of pages4
StatePublished - Apr 2019


  • Genomic profiling
  • Metaplastic breast cancer
  • Triple negative
  • Tumor-infiltrating lymphocytes

ASJC Scopus subject areas

  • Surgery


Dive into the research topics of 'Metaplastic breast cancers: Genomic profiling, mutational burden and tumor-infiltrating lymphocytes'. Together they form a unique fingerprint.

Cite this